Related Experiment Video
Updated: Jun 23, 2026

09:07
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.2K
Dopamine depletion in wistar rats with epilepsy
E M Trindade-Filho1,2, J Dal Pai3, D N de Castro1
1Centro Universitário - CESMAC, Campus I, Maceió, AL, Brasil.
Summary
Dopamine depletion in rats increased seizure severity in the acute phase of epilepsy, suggesting dopamine
Area of Science:
- Neuroscience
- Epilepsy Research
- Neuropharmacology
Background:
- Dopamine's role in neuronal excitability is studied during seizure vulnerability.
- Previous research links dopamine to neuronal excitability and seizure susceptibility.
- The substantia nigra pars compacta is a key dopamine-producing region.
Purpose of the Study:
- To investigate the effects of dopamine depletion on seizure susceptibility and severity.
- To determine the impact of dopamine depletion on spontaneous recurrent seizures (SRSs) frequency.
- To measure dopamine levels in the hippocampus following drug administration.
Main Methods:
- Administration of 6-hydroxidopamine (6-OHDA) to deplete dopamine in the substantia nigra pars compacta of male rats.
- Utilized the pilocarpine model of epilepsy to induce seizures and status epilepticus (SE).
- Assessed susceptibility to pilocarpine-induced SE and SRSs frequency during the chronic phase.
Main Results:
- 6-OHDA pre-treated rats showed a higher incidence of motor limbic seizures evolving to SE (62%) compared to controls (45%).
- Seizure severity during the acute phase was significantly higher in the 6-OHDA group (56.52%) than in controls (4.16%).
- No significant change in SRSs frequency was observed between groups during the chronic phase.
Conclusions:
- Dopamine depletion significantly increases seizure severity in the acute phase of the pilocarpine model.
- Dopamine appears to exert an inhibitory effect on the motor expression of seizures.
- The findings suggest a crucial role for dopamine in modulating seizure severity, particularly in the acute stage.

